Aim Clinical trials have demonstrated the efficacy of the tetravalent human papillomavirus
(HPV) vaccination in the prevention of cervical cancer and genital warts associated with …

Cytology-based screening has reduced cervical cancer mortality in countries able to
implement, sustain and financially support organized programs that achieve broad …

Background Despite the fact that approximately 70% of Canadian women undergo cervical
cancer screening at least once every 3 years, approximately 1,300 women were diagnosed …

Background Candidate human papillomavirus (HPV) vaccines have demonstrated almost
90%-100% efficacy in preventing persistent, type-specific HPV infection over 18 mo in …

Background Vaccination against human papillomavirus (HPV) to prevent cervical cancer
(CC) primarily targets young girls before sexual debut and is cost-effective. We assessed …

Objective This study aimed at evaluating the cost-effectiveness of human papillomavirus
virus (HPV) vaccination in France, using a generally applicable succinct cohort model …

Background Seventy percent of sexually active individuals will be infected with Human
Papillomavirus (HPV) during their lifetime. These infections are incriminated for almost all …

Background Current prophylactic vaccines against human papillomavirus (HPV) target two
of the most oncogenic types, HPV-16 and-18, which contribute to roughly 70% of cervical …

In Germany, vaccination against the most oncogenic HPV types 16/18 is recommended by
the Standing Committee on Vaccination (STIKO) for 12–17 year old girls since March 2007 …

Cervical cancer incidence and mortality have decreased in high-income countries, but low-
and middle-income countries continue to bear a significant burden from the disease. Human …